HIA
CORT icon

HFM Investment Advisors’s Corcept Therapeutics CORT Stock Holding History

HFM Investment Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4
Closed -$140 – 1233
2025
Q4 		$140 Sell
4
-2
-33% -$157 ﹤0.01% 1113
2025
Q3 		$499 Sell
6
-1
-14% -$72 ﹤0.01% 659
2025
Q2 		$514 Buy
7
+5
+250% +$363 ﹤0.01% 641
2025
Q1 		$229 Buy
+2
New +$122 ﹤0.01% 580

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

HFM Investment Advisors's CORT Position: Q1 2026 in Review

HFM Investment Advisors sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 4 shares — an estimated $140 sold.

HFM Investment Advisors first reported a position in CORT in Q1 2025 and held it in 4 quarters. The position peaked at $514 in Q2 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • HFM Investment Advisors reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • HFM Investment Advisors sold 4 Corcept Therapeutics shares in Q1 2026, an estimated $140.
  • HFM Investment Advisors first reported a position in Corcept Therapeutics in Q1 2025 and held it in 4 quarters.
  • HFM Investment Advisors's Corcept Therapeutics position peaked at $514 in Q2 2025.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on HFM Investment Advisors's 13F filing for Q1 2026, filed 1 May 2026.